This document discusses small aperture optics for improving vision, including the KAMRA corneal inlay and IC-8 intraocular lens. It summarizes clinical studies that show the KAMRA inlay and IC-8 IOL provide an extended depth of focus, improving intermediate and near vision while maintaining good distance vision. The document also notes that these technologies are capturing more market share and have the potential to address a significant segment of patients with aberrated corneas.

1. Transforming Vision
With Small Aperture Optics
Yari L. Mitchell
Vice President, Medical Affairs & Business Strategy
OIS@ASCRS – May 4, 2017

2. W o r d s
W o r d s
W o r d s
W o r d s
Y o u r W h o l e W o r l d
W o r d s

5. Single Focus Challenge
20/16 at Far
20/50 at Intermediate
20/100 at Near
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
2.00 1.50 1.00 0.50 0.00 -0.50 -1.00 -1.50 -2.00 -2.50 -3.00 -3.50 -4.00
LogMARAcuity
Defocus (D)
Defocus Curve
Mean BCDVA
Functional
Range of
Vision
* Presbyopic patient defocus curve – KAMRA Inlay PMA (N=114)

6. Benefits of Small Aperture
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
-4.00-3.50-3.00-2.50-2.00-1.50-1.00-0.500.000.501.001.502.00
LogMARAcuity
Defocus (D)
Binocular Defocus Curve (IC-8® IOL with Monofocal IOL)
* Mean BSCVA defocus curve collected in a subgroup at 6 months (N=12)
Functional
Range of
Vision
20/20 at Intermediate
20/30 at Near
20/16 at Far

7. Quantity and Quality
0.0D +0.5D +1.0D +1.5D +2.0D +3.0D
IC-8® IOL
Target-corrected
to -0.75D
Symfony IOL
AcriLisa
Trifocal IOL
(Far Focus) (Near Focus)(Intermediate Focus)

8. The IC-8 IOL is not approved for use in the United States
KAMRA® Inlay IC-8® Intraocular Lens

9. Creating the Corneal Inlay Market

10. KAMRA® Inlay in the Real World
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Preop Month 1 Month 3 Month 6
LogMARAcuity
Visit
UCDVA
UCDVA IE UCDVA OU
-0.20
-0.10
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
Preop Month 1 Month 3 Month 6
LogMARAcuity
Visit
UCNVA
UCNVA IE UCNVA OU
N=337 N=248N=328N=271

11. KAMRAInlay

12. Taking Share in a Crowded IOL Market

13. Uncorrected Visual Acuity
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Mon 1 (n=108) Mon 3 (n=107) Mon 6 (n=105)
logMAR
Binocular UCVA (Mean, 95%CI)
Far Intermediate Near
European Post-Market IC-8® Study Outcomes
The IC-8 IOL is not approved for use in the United States

14. Virgin Eyes

15. 86.5%
7.5%
5.4%
0.3%
0.3%
Monofocal
Toric
Presbyopia-correcting
Phakic
Other
IC-8® IOL Opportunity
*Estimate based on prevalence of LVC, corneal aberrations > 0.5 microns and keratoconus and
reported 2016 US IOL adoption data from the 2016 Market Scope IOL Report
11%
Aberrated
Cornea Segment*
2016 Market Scope IOL Report – US IOL Adoption
The IC-8 IOL is not approved for use in the United States